Eli Lilly and Company Announces Approvable Letter Issued by FDA for Arxxant(TM) (ruboxistaurin mesylate) (PR Newswire via Yahoo! Finance)
Eli Lilly and Company announced today that it received an approvable letter from the U.S. Food and Drug Administration for ruboxistaurin mesylate (proposed trade name Arxxant, pronounced, ark-ZONT), its investigational oral therapy being studied for treatment of diabetic retinopathy , a diabetic eye disease.

Orchid gets FDA okay for Cefotaxime injections (New Kerala)
Chennai, Aug 16: Orchid Chemicals & Pharmaceuticals, a leading player in the Indian drug industry, has received a formal approval from the US Food and Drug Authority (FDA) for three of its abbreviated new drug applications (ANDAs) for Cefotaxime.